Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Analyze & Realize | NETWORK |
Not provided
Not provided
Not provided
Not provided
Study to evaluate the effect of gum acacia (FibregumTM) on post-prandial glucose and insulin levels and food intake in normal-weight and overweight subjects during a 2-7 weeks intervention period. In addition, tolerability and safety of gum acacia (FibregumTM) will be assessed.
Gum arabic is a heteropolysaccharide (molecular weight 350-850 kDa) harvested from Acacia seyal or Acacia senegal. It is highly soluble and broadly used in numerous solid and liquid food matrices.
For the assessment of non-digestible carbohydrates as dietary fiber, it is eminent to demonstrate that its consumption is related to a specific beneficial physiological effect shown in an appropriate clinical study. The aim of the present trial was to expand the clinical evidence with respect to beneficial effects of gum acacia on post-prandial blood glucose levels, post-prandial insulin levels and prospective ad libitum food intake, in normal-weight and overweight subjects.
The present double-blind, randomized, controlled, three-way cross-over study was to evaluate the effect of gum acacia versus no treatment on post-prandial glucose (PPG) levels in normal-weight and overweight subjects during a 2-7 weeks intervention period.
Additionally, post-prandial insulin (PPI) levels, prospective ad libitum food intake, as well as the safety and tolerability of gum acacia were assessed.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 40 g (D1) | Active Comparator | 40 g gum acacia powder (D1). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4). |
|
| 20 g (D2) | Active Comparator | 20 g gum acacia powder (D2). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4). |
|
| No treatment (NT) | Other | 0 g gum acacia powder. Standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 40 g Gum acacia (FibregumTM) | Dietary Supplement | Applied in 300 mL of orange juice with breakfast (single use at visit) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in blood glucose incremental AUC 0-120 min between D1 verum group and no treatment group | Venous blood samples were drawn for the determination of glucose values, with sampling times at -15 min and immediately prior to the intake of the standardized breakfast (time "0") as well as 15, 30, 45, 60, 90 and 120 min after the "0 min" blood draw. | 2 -7 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Difference in blood glucose incremental AUC 0-120 min between D2 verum group and no treatment group | Venous blood samples were drawn for the determination of glucose values, with sampling times at -15 min and immediately prior to the intake of the standardized breakfast (time "0") as well as 15, 30, 45, 60, 90 and 120 min after the "0 min" blood draw. | 2 -7 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Gastrointestinal tolerability evaluation (by 4-point scale), in comparison between each verum group and no treatment group | Gastrointestinal tolerabilty was assessed by assessing the items burping, cramping, distension, flatulence, nausea, vomiting scored by means of a 4-point scale: 1=none, 2=mild, 3=moderate, 4=severe, on test days only, at 0 min (before the standardized breakfast) and at 1, 2, 3, 4, 6, 12 and 24 hours after intake of standardized breakfast in the subject diary |
Inclusion Criteria:
Men and women from 25 to 60 years old
Body mass index (BMI) 18.5 kg/m2 - 29.9 kg/m2
Generally in good health
Normal fasting blood glucose (FBG) 3.9 to <5.6 mmol/L (70 to <100 mg/dL) and HbA1c of 4 to <5.7 %
Regularly consuming 3 main meals/day, with breakfast and lunch as dominant meals
Familiar with components of the study meals, no disliking and/or extreme preferences for any of the items
Readiness to comply with study procedures, in particular:
Stable body weight in the last 3 months prior to V1 (≤3% self-reported change)
Stable concomitant medications (if any) for at least last 3 months prior to V1
Women of childbearing potential:
Readiness not to participate in another clinical study during this study
Exclusion Criteria:
Known allergy or hypersensitivity to the components of the investigational product / study meals
History and/or presence of clinically significant self-reported disorder as per investigator's judgement:
Subjects with difficult vein access or sensitive to blood draws
Nighttime eating/snacking (after 10 pm)
Excessive consumption of artificial sweeteners (e.g. in beverages)
History and/or presence of eating disorders like bulimia, anorexia nervosa, binge-eating as per investigator's judgement
Use of treatment/supplementation in the last 2 months prior to V1 and during the study, as per investigator's judgment, that could influence gastrointestinal functions, body weight, blood glucose levels or otherwise interfere with study conduct / evaluation
Deviation of safety laboratory parameter(s) at V1 (except for Hb and HbA1c) that is:
Diet/weight loss programs within the last 3 months prior to V1 and during the study
Recent blood donation within the last 1 month prior to study
Smoking within the last 6 months prior to V1 and during the study
Vegetarian, vegan or other restrictive diet
Night shift work
History or current abuse of alcohol, drug and/or medication
Women of child-bearing potential: pregnancy or nursing
Inability to comply with study procedures
Participation in another study during the last 30 days prior to V1
Any other reason deemed suitable for exclusion, per investigator's judgment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Analyze & Realize | Berlin | 10369 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050177 | Overweight |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
| ID | Term |
|---|---|
| D006170 | Gum Arabic |
| ID | Term |
|---|---|
| D053149 | Plant Gums |
| D001704 | Biopolymers |
| D011108 | Polymers |
| D046911 | Macromolecular Substances |
Not provided
Not provided
Double-blind, randomized, controlled, three-way cross-over design, monocentric nutritional study
Not provided
Not provided
Not provided
| 20 g Gum acacia (FibregumTM) | Dietary Supplement | Applied in 300 mL of orange juice with breakfast (single use at visit) |
|
|
| 0 g Gum acacia (FibregumTM) | Dietary Supplement | 300 mL of orange juice with breakfast (single use at visit) |
|
|
| Food (energy) intake at ad libitum lunch, in comparison between each verum group vs no treatment group | Food was weighed before the subject consumed the meal and afterwards and the energy content of the food consumed was determined. | 2 -7 weeks |
| Individual appetite sensation items (VAS for satiety, hunger, fullness, prospective consumption, desire to eat), in comparison between each verum group vs no treatment group - VAS values at all time points 0, 15, 30, 45, 60, 90, 120, 180, 210, 240 min | Visual analogue scales (VAS) for satiety, hunger, fullness, prospective consumption, desire to eat will be reported as follows: Subjects had to record their appetite sensation before and after consumption of the standardised breakfast provided on site. VAS, 100-mm in length, were used to assess the following items:
| 2 -7 weeks |
| Individual appetite sensation items (VAS for satiety, hunger, fullness, prospective consumption, desire to eat), in comparison between each verum group vs no treatment group - maximal/minimal VAS values | Visual analogue scales (VAS) for satiety, hunger, fullness, prospective consumption, desire to eat will be reported as follows: Subjects had to record their appetite sensation before and after consumption of the standardised breakfast provided on site. VAS, 100-mm in length, were used to assess the following items:
| 2 -7 weeks |
| Individual appetite sensation items (VAS for satiety, hunger, fullness, prospective consumption, desire to eat), in comparison between each verum group vs no treatment group - total AUC 0-15, 0-30, 0-45, 0-60, 0-90, 0-120, 0-180, 0-210, 0-240 min | Visual analogue scales (VAS) for satiety, hunger, fullness, prospective consumption, desire to eat will be reported as follows: Subjects had to record their appetite sensation before and after consumption of the standardised breakfast provided on site. VAS, 100-mm in length, were used to assess the following items:
| 2 -7 weeks |
| Individual appetite sensation items (VAS for satiety, hunger, fullness, prospective consumption, desire to eat), in comparison between each verum group vs no treatment group - incremental AUC 0-15, 0-30, 0-45, 0-60, 0-90, 0-120, 0-180, 0-210, 0-240 min | Visual analogue scales (VAS) for satiety, hunger, fullness, prospective consumption, desire to eat will be reported as follows: Subjects had to record their appetite sensation before and after consumption of the standardised breakfast provided on site. VAS, 100-mm in length, were used to assess the following items:
| 2 -7 weeks |
| Composite score ([desire to eat + hunger + (100-fullness) + prospective consumption]/4), in comparison between each verum group vs no treatment group - VAS values at all time points 0, 15, 30, 45, 60, 90, 120, 180, 210, 240 min | Composite score is calculated as follows:([desire to eat + hunger + (100 - satiety) + estimated consumption]/4). Subjects had to record their appetite sensation before and after consumption of the standardised breakfast provided on site. Visual analogue scales (VAS), 100-mm in length, were used to assess the following items:
| 2 -7 weeks |
| Composite score ([desire to eat + hunger + (100-fullness) + prospective consumption]/4), in comparison between each verum group vs no treatment group - maximal/minimal VAS values | Composite score is calculated as follows:([desire to eat + hunger + (100 - satiety) + estimated consumption]/4). Subjects had to record their appetite sensation before and after consumption of the standardised breakfast provided on site. Visual analogue scales (VAS), 100-mm in length, were used to assess the following items:
| 2 -7 weeks |
| Composite score ([desire to eat + hunger + (100-fullness) + prospective consumption]/4), in comparison between each verum group vs no treatment group - total AUC 0-15, 0-30, 0-45, 0-60, 0-90, 0-120, 0-180, 0-210, 0-240 min | Composite score is calculated as follows:([desire to eat + hunger + (100 - satiety) + estimated consumption]/4). Subjects had to record their appetite sensation before and after consumption of the standardised breakfast provided on site. Visual analogue scales (VAS), 100-mm in length, were used to assess the following items:
| 2 -7 weeks |
| Composite score ([desire to eat + hunger + (100-fullness) + prospective consumption]/4), in comparison between each verum group vs no treatment group - incremental AUC 0-15, 0-30, 0-45, 0-60, 0-90, 0-120, 0-180, 0-210, 0-240 min | Composite score is calculated as follows:([desire to eat + hunger + (100 - satiety) + estimated consumption]/4). Subjects had to record their appetite sensation before and after consumption of the standardised breakfast provided on site. Visual analogue scales (VAS), 100-mm in length, were used to assess the following items:
| 2 -7 weeks |
| 24 hour energy intake on test days: breakfast+ad libitum lunch+diary records, in comparison between each verum group vs no treatment group | After each of the site visits on test days, food and beverage intake during the time period until 24 hours after start of site visit had to be documented by the subjects in the study diary and the energy. | 2 -7 weeks |
| PPG, in comparison between each verum group vs no treatment group - concentration at all time points 0, 15, 30, 45, 60, 90, 120, 180 min | Venous blood samples were drawn for the determination of glucose values | 2 -7 weeks |
| PPG, in comparison between each verum group vs no treatment group - maximal concentration | Venous blood samples were drawn for the determination of glucose values | 2 -7 weeks |
| PPG, in comparison between each verum group vs no treatment group - total AUC 0-15, 0-30, 0-45, 0-60, 0-90, 0-120, 0-180 min | Venous blood samples were drawn for the determination of glucose values | 2 -7 weeks |
| PPG, in comparison between each verum group vs no treatment group - incremental AUC 0-15, 0-30, 0-45, 0-60, 0-90, 0-180 min | Venous blood samples were drawn for the determination of glucose values | 2 -7 weeks |
| PPI, in comparison between each verum group vs no treatment group - concentration at all time points 0, 15, 30, 45, 60, 90, 120, 180 min | Venous blood samples were drawn for the determination of insulin values | 2 -7 weeks |
| PPI, in comparison between each verum group vs no treatment group - maximal concentration | Venous blood samples were drawn for the determination of insulin values | 2 -7 weeks |
| PPI, in comparison between each verum group vs no treatment group - total AUC 0-15, 0-30, 0-45, 0-60, 0-90, 0-120, 0-180 min | Venous blood samples were drawn for the determination of insulin values | 2 -7 weeks |
| PPI, in comparison between each verum group vs no treatment group - incremental AUC 0-15, 0-30, 0-45, 0-60, 0-90, 0-120, 0-180 min | Venous blood samples were drawn for the determination of insulin values | 2 -7 weeks |
| Global evaluation (by 4-point scale) of benefit by subject and the investigator, in comparison between each verum group vs no treatment group | The investigators had to evaluate the benefit of the treatment type (global scaled evaluation with "very good", "good", "moderate" and "poor"). | 2 -7 weeks |
| 2 -7 weeks |
| Blood pressure (systolic and diastolic), in comparison between each verum group and no treatment group | Sitting blood pressure (systolic and diastolic) was measured using standard procedures | 2 -7 weeks |
| Pulse rate, in comparison between each verum group and no treatment group | Sitting pulse rate was measured using standard procedures | 2 -7 weeks |
| Global evaluation (by 4-point scale) of tolerability by subject and investigator at study end, in comparison between each verum group and no treatment group | The investigators had to evaluate the tolerability of the treatment type (global scaled evaluation with "very good", "good", "moderate" and "poor"). | 2 -7 weeks |
| Assessment of adverse events throughout the study | Any adverse event (AE) that occured during the course of the clinical study had to be recorded | 2 -7 weeks |
| Body weight, in comparison between each verum group and no treatment group | Body weight (kg) was measured in subjects in fasting condition wearing only underwear and barefoot, after emptying the bladder and bowels as needed, using standardized weighing scales (Tanita BC-420MA). | 2 -7 weeks |
| Changes in dietary habits, physical activities and sleep habits by questioning, in comparison between each verum group and no treatment group | The subjects were questioned with respect to any changes:
| 2 -7 weeks |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011134 |
| Polysaccharides |
| D002241 | Carbohydrates |
| D053147 | Plant Exudates |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |